Close Menu

Invitae

The sequencing company reported preliminary fourth quarter revenues of $27 million and said it currently has $318 million in cash and investments.

Invitae is working with Bristol Myers Squibb, Janssen, Novartis, and Genentech to advance an NGS panel to gauge the efficacy of AML treatments in trials.

Qiagen's CEO discussed the company's focus on specific growth drivers, while Invitae's CEO talked about pandemic-related challenges in its genetic testing business.

The partners will use PacBio's HiFi sequencing to develop assays for carrier screening, evaluating immune system responses, and diagnosing heritable diseases.

The company's preliminary annual revenues beat the consensus Wall Street estimate of $274.9 million.

Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.

Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.

The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.

The firms said they are collaborating to facilitate genetic testing to support early diagnosis of GM1, a rare monogenic recessive lysosomal storage disease.

The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate. 

Pages

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.